Research News
Updates from the published research literature: new studies, comparative analyses, and regulatory context.
Longevity Peptide Research Updates: Epithalon, SS-31, and NAD+ Studies
Recent telomere-pathway, mitochondrial-protector, and NAD+ research updates from the longevity literature.
Gut-Pathway Peptide Research: BPC-157, KPV, and GI Models
Recent gut-pathway peptide research, including BPC-157 and KPV-containing stack literature.
Thymic Peptide Immunology: Recent Research on TA-1 and Thymalin
Updated thymic peptide immunology research and what it shows about Thymosin Alpha-1 and Thymalin pathways.
Nootropic Peptide Research Updates: SEMAX, Selank, and Cognition Studies
Recent attention, anxiolytic, and neuroprotection research updates on SEMAX, Selank, and DSIP.
GH-Axis Research Updates: What New Studies Mean for Researchers
Recent GH-axis research updates across GHRH analogs and ghrelin-mimetic compounds.
Melanocortin Research Updates: PT-141, Melanotan, and MC Receptor Selectivity
Recent melanocortin pharmacology research and what it shows about MC1R-MC5R selectivity.
Latest Mitochondrial Peptide Research: MOTS-c, SS-31, and Beyond
Recent mitochondrial-derived peptide research, including MOTS-c findings and Szeto-Schiller tetrapeptide updates.
Triple-Agonist Research Updates: GLP-1, GIP, and Glucagon Receptor Studies
Where triple-agonist research stands across the GLP-1, GIP, and glucagon receptor family.
New Peptide Research Published This Quarter (Q2 2026)
Roundup of newly published peptide research papers from the last quarter, summarized for research-buyer reference.
FDA Compounding Policy: What It Means for Research Peptide Supply
How the current FDA compounding pharmacy policy environment affects the research-use-only peptide market.
What 2026 BPC-157 Studies Show: Updates from the Research Literature
Summary of the most recent BPC-157 research, including new mechanism studies and updated pathway findings.
Retatrutide vs Tirzepatide: Where the 2026 Research Stands
How the latest comparative research positions Retatrutide and Tirzepatide in the incretin agonist landscape.